Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

144 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone.
Wesson DE, Simoni J, Broglio K, Sheather S. Wesson DE, et al. Among authors: broglio k. Am J Physiol Renal Physiol. 2011 Apr;300(4):F830-7. doi: 10.1152/ajprenal.00587.2010. Epub 2011 Jan 26. Am J Physiol Renal Physiol. 2011. PMID: 21270096
Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy.
Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE. Mahajan A, et al. Kidney Int. 2010 Aug;78(3):303-9. doi: 10.1038/ki.2010.129. Epub 2010 May 5. Kidney Int. 2010. PMID: 20445497 Clinical Trial.
Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR.
Phisitkul S, Khanna A, Simoni J, Broglio K, Sheather S, Rajab MH, Wesson DE. Phisitkul S, et al. Among authors: broglio k. Kidney Int. 2010 Apr;77(7):617-23. doi: 10.1038/ki.2009.519. Epub 2010 Jan 13. Kidney Int. 2010. PMID: 20072112 Clinical Trial.
A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia.
Vu K, Busaidy N, Cabanillas ME, Konopleva M, Faderl S, Thomas DA, O'Brien S, Broglio K, Ensor J, Escalante C, Andreeff M, Kantarjian H, Lavis V, Yeung SC. Vu K, et al. Among authors: broglio k. Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):355-62. doi: 10.1016/j.clml.2012.05.004. Epub 2012 Jun 1. Clin Lymphoma Myeloma Leuk. 2012. PMID: 22658895 Free PMC article. Clinical Trial.
Age and associated fibrocystic changes are prognostically significant in patients with small node-negative (T1a,bN0) invasive breast cancer.
Durak MG, Gonzalez-Angulo AM, Hanrahan EO, Broglio KR, Valero V, Hortobagyi GN, Hunt KK, Sahin AA. Durak MG, et al. Among authors: broglio kr. Breast J. 2011 Sep-Oct;17(5):462-9. doi: 10.1111/j.1524-4741.2011.01116.x. Epub 2011 Jul 5. Breast J. 2011. PMID: 21726347
Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma.
Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, Valero V. Hanrahan EO, et al. J Clin Oncol. 2007 Nov 1;25(31):4952-60. doi: 10.1200/JCO.2006.08.0499. J Clin Oncol. 2007. PMID: 17971593
Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer.
Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, Broglio KR, Yin G, Esmaeli B, Hortobagyi GN, Valero V. Rivera E, et al. Among authors: broglio kr. Cancer. 2008 Apr 1;112(7):1455-61. doi: 10.1002/cncr.23321. Cancer. 2008. PMID: 18300256 Clinical Trial.
Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease.
Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE, Hortobagyi GN. Cristofanilli M, et al. Cancer. 2007 Oct 1;110(7):1436-44. doi: 10.1002/cncr.22927. Cancer. 2007. PMID: 17694554
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Buzdar AU, et al. Among authors: broglio kr. Clin Cancer Res. 2007 Jan 1;13(1):228-33. doi: 10.1158/1078-0432.CCR-06-1345. Clin Cancer Res. 2007. PMID: 17200359 Clinical Trial.
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF. Romaguera JE, et al. J Clin Oncol. 2005 Oct 1;23(28):7013-23. doi: 10.1200/JCO.2005.01.1825. Epub 2005 Sep 6. J Clin Oncol. 2005. PMID: 16145068 Clinical Trial.
144 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback